Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: July 21, 2010
Last updated: August 3, 2011
Last verified: July 2010
Malignant Melanoma is a deadly skin cancer that can be cured if diagnosed early. To date atypical pigmented skin lesions are diagnosed by appearance alone and many moles and lesions are excised unnecessarily and on the other hand malignant lesions are missed and diagnosed too late. In this study a protein conjugated to a florescent dye is spread on a suspicious pigmented lesion, the hypothesis is that this protein binds to malignant cells only and thus with a special camera that picks up the dye we can find pigmented lesions with early malignant transformation.

Malignant Melanoma
Pigmented Nevi
Skin Neoplasm

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Early Diagnosis of Malignant Melanoma Transformation in Pigmentary Skin Lesions

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 50
Study Start Date: July 2010
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy individuals above 18 years of age with pignented skin lesions indicated for excision

Inclusion Criteria:

  • pigmented lesion indicated for surgical excision
  • over 18 years of age

Exclusion Criteria:

  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01167998

Contact: Sharon Merims, MD 972-2-6777745

: Hadassah Medical Organization, Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD    : 00 972 2 6776095   
Contact: Hadas Lemberg, PhD    : 00 972 2 6777572   
Principal Investigator: Sharon Merims, MD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Responsible Party: Catherine Shachaf, Orlucent Inc Identifier: NCT01167998     History of Changes
Other Study ID Numbers: orlucent-HMO-CTIL 
Study First Received: July 21, 2010
Last Updated: August 3, 2011
Health Authority: israel : Ministry of Health - Director General

Additional relevant MeSH terms:
Nevus, Pigmented
Nevi and Melanomas
Skin Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms by Site
Skin Diseases processed this record on October 21, 2016